As federal oversight evolves, states are increasingly stepping in to regulate key aspects of the life sciences and health care industries. From drug pricing and hospital discount programs to drug take-back laws, data privacy and environmental responsibility – a wave of new state laws is creating a complex and varied regulatory landscape. This panel will explore the latest state-level legislative trends and their impact on the industry. Discussion topics include:

• Examining the rise of state-driven drug pricing regulations
  • How to understand and comply with conflicting and colliding pricing requirements across different states
• Assessing new state hospital drug discount requirements, conflicts with the federal 340B Drug Pricing Program, and ensuing litigation challenging the state’s authority in this area
• An analysis of state-by-state drug take-back laws
  • Understanding pharmaceutical manufacturer responsibilities with regard to public education and awareness, as well as the collection, transport and proper disposal of unwanted drug
• An overview of state health privacy laws and their impact on life sciences companies
  • Key risks associated with collecting and sharing consumer health-related data
  • Best practices for data protection, consent management, and compliance frameworks
  • Strategies to adapt to evolving regulations and avoid enforcement actions
• Emerging Extended Producer Responsibility (EPR) laws—what they mean for life sciences industry manufacturers
• How businesses can navigate the patchwork of state laws while maintaining national and global operations
• Strategies for anticipating and adapting to future state-level regulatory shifts